Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process

References

• Bollag G, Freeman S, Lyons JF, Post LE. (2003). Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 4:1436–1441.
   PubMedGoogle Scholar
• Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599.
   PubMed Web of Science ®Google Scholar
• Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IF. (2008). Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 44:142–150.
   PubMed Web of Science ®Google Scholar
• Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, Moliterni J, Huby N, Fotouhi N, Liu M, Goelzer P, Sandhu HK, Li JK, Railkar A, Heimbrook D, Niu H. (2010). Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. Mol Cancer Ther 9:134–144.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. (2002). Mutations of the BRAF gene in human cancer. Nature 417:949–954.
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P. (2009). Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (Meeting Abstracts) 27 (15S): 9000-.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Hodi FS, Bastian BC. (2010). Mutation-driven drug development in melanoma. Curr Opin Oncol 22:178–183.
   PubMed Web of Science ®Google Scholar
• Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. (2008). Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm 5:1003–1019.
   PubMed Web of Science ®Google Scholar
• Gollob JA, Wilhelm S, Carter C, Kelley SL. (2006). Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33:392–406.
   PubMed Web of Science ®Google Scholar
• Huang CY, Ferrell JE Jr. (1996). Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 93:10078–10083.
   PubMed Web of Science ®Google Scholar
• Jang SH, Wientjes MG, Lu D, Au JL. (2003). Drug delivery and transport to solid tumors. Pharm Res 20:1337–1350.
   PubMed Web of Science ®Google Scholar
• Kelland LR. (2004). Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827–836.
   PubMed Web of Science ®Google Scholar
• Li N, Batt D, Warmuth M. (2007). B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 8:452–456.
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281–5293.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Robertson GP. (2008). Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 68:5–8.
   PubMed Web of Science ®Google Scholar
• Mager DE, Woo S, Jusko WJ. (2009). Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16–24.
   PubMed Web of Science ®Google Scholar
• Mager DE, Wyska E, Jusko WJ. (2003). Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510–518.
   PubMed Web of Science ®Google Scholar
• Martinez M, Amidon G, Clarke L, Jones WW, Mitra A, Riviere J. (2002). Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Adv Drug Deliv Rev 54:825–850.
   PubMed Web of Science ®Google Scholar
• Mercer KE, Pritchard CA. (2003). Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25–40.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Nathanson KL, Chapman PB, Xu X, Sosman JA, McArthur GA, Ribas A, Kim KB, Grippo JF, Flaherty KT. (2009). PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. J Clin Oncol (Meeting Abstracts) 27(15S):9021-.
   PubMed Web of Science ®Google Scholar
• Rowland M, Tozer TN. 1995. Clinical Pharmacokinetics: concepts and applications. Philadephia: Lippincott Williams & Wilkins.
   Google Scholar
• Sausville EA, Burger AM. (2006). Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66:3351–4, discussion 3354.
   Web of Science ®Google Scholar
• Schreck R, Rapp UR. (2006). Raf kinases: oncogenesis and drug discovery. Int J Cancer 119:2261–2271.
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. (2007). Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308.
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Herrera R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937–947.
   PubMed Web of Science ®Google Scholar
• Shepherd C, Puzanov I, Sosman JA. (2010). B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 12:146–152.
   PubMed Web of Science ®Google Scholar
• Smith AL, DeMorin FF, Paras NA, Huang Q, Petkus JK, Doherty EM, Nixey T, Kim JL, Whittington DA, Epstein LF, Lee MR, Rose MJ, Babij C, Fernando M, Hess K, Le Q, Beltran P, Carnahan J. (2009). Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline. J Med Chem 52:6189–6192.
   PubMed Web of Science ®Google Scholar
• Tanaka C, O’Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. (2008). Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596–1602.
   PubMedGoogle Scholar
• Teicher BA. (2006). Tumor models for efficacy determination. Mol Cancer Ther 5:2435–2443.
   PubMed Web of Science ®Google Scholar
• Wang S, Guo P, Wang X, Zhou Q, Gallo JM. (2008). Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 7:407–417.
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Hurlstone A. (2010). BRAF as therapeutic target in melanoma. Biochem Pharmacol 80:561–567.
   PubMed Web of Science ®Google Scholar
• Wenglowsky S, Ren L, Ahrendt KA, Laird ER, Aliagas I, Alicke B, Buckmelter AJ, Choo EF, Dinkel V, Feng B, Gloor SL, Gould SE, Gross S, Gunzner-Toste J, Hansen JD, Hatzivassiliou G, Liu B, Malesky K, Mathieu S, Newhouse B, Raddatz NJ, Ran Y, Rana S, Randolph N, Risom T, Rudolph J, Savage S, Selby LT, Shrag M, Song K, Sturgis HL, Voegtli WC, Wen Z, Willis BS, Woessner RD, Wu W-I, Young WB, Grina J. (2011). Pyrazolopyridine inhibitors of B-RafV600E. Part 1: The development of selective, orally bioavailable, and efficacious inhibitors. ACS Med Chem Lett 2:342–347.
   PubMed Web of Science ®Google Scholar
• Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF. (2009). Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther 329:360–367.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T. (2008). Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267–1274.
   PubMed Web of Science ®Google Scholar
• Zebisch A, Troppmair J. (2006). Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci 63:1314–1330.
   PubMed Web of Science ®Google Scholar